Saturday 17 October 2026
Export NMRA’s income statement to Excel — free account
Neumora Therapeutics, Inc.
NMRA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 30.3%, free cash flow grew 24.5% and total debt rose 172.0%, each against the same quarter a year earlier.
0.47
0.04
+9.30%
Follow NMRA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (187.11%) | (148.74%) | (121.21%) | (104.35%) |
+8 more TTM periods Free account |
|
| (121.89%) | (108.32%) | (93.28%) | (89.11%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(219.05%) | (180.29%) | (149.83%) | (156.16%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.97) | (1.07) | (1.26) | (1.29) | |
Free Cash Flow |
(180.31) | (193.11) | (206.27) | (208.75) | |
Capital Expenditures |
0.21 | 0.29 | 0.17 | 0.07 | |
| Other line items | |||||
Cash ROIC |
(84.16%) | (71.33%) | (60.50%) | (64.58%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(32.71) | (43.97) | (34.17) | (28.59) | |
Operating CF/Net income |
0.85 | 0.87 | 0.87 | 0.88 | |
Depreciation/Fixed assets |
40.64 | 1.28 | (37.92) | (44.02) | |
Capex/Depreciation |
0.20 | 7.05 | (0.11) | (0.02) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.97) | (1.08) | (1.26) | (1.29) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates